Study Title: A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Albert Lockhart, at lockhara@musc.edu.Study Coordinator, Bria Sanders, at sandebri@musc.edu.Trial opened at the following institutions: Medical University of South Carolina